Literature DB >> 28626882

Quantitative proteome analysis of plasma microparticles for the characterization of HCV-induced hepatic cirrhosis and hepatocellular carcinoma.

Raghda Saad Zaghloul Taleb1,2, Pacint Moez2, Doreen Younan2, Martin Eisenacher1, Matthias Tenbusch3, Barbara Sitek1, Thilo Bracht1.   

Abstract

PURPOSE: Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor and a leading cause of cancer-related deaths worldwide. Cirrhosis induced by hepatitis-C virus (HCV) infection is the most critical risk factor for HCC. However, the mechanism of HCV-induced carcinogenesis is not fully understood. Plasma microparticles (PMP) contribute to numerous physiological and pathological processes and contain proteins whose composition correlates to the respective pathophysiological conditions. EXPERIMENTAL
DESIGN: We analyzed PMP from 22 HCV-induced cirrhosis patients, 16 HCV-positive HCC patients with underlying cirrhosis and 18 healthy controls. PMP were isolated using ultracentrifugation and analyzed via label-free LC-MS/MS.
RESULTS: We identified 840 protein groups and quantified 507 proteins. 159 proteins were found differentially abundant between the three experimental groups. PMP in both disease entities displayed remarkable differences in the proteome composition compared to healthy controls. Conversely, the proteome difference between both diseases was minimal. GO analysis revealed that PMP isolated from both diseases were significantly enriched in proteins involved in complement activation, while endopeptidase activity was downregulated exclusively in HCC patients.
CONCLUSION: This study reports for the first time a quantitative proteome analysis for PMP from patients with HCV-induced cirrhosis and HCC. Data are available via ProteomeXchange with identifier PXD005777.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Hepatic cirrhosis; Hepatitis-C virus; Hepatocellular carcinoma; Label-free proteomics; Plasma microparticles

Mesh:

Substances:

Year:  2017        PMID: 28626882     DOI: 10.1002/prca.201700014

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  4 in total

Review 1.  Clinical Applications of Liquid Biopsy in Hepatocellular Carcinoma.

Authors:  Jin-Cui Yang; Jun-Jie Hu; Yi-Xin Li; Wei Luo; Jin-Zhou Liu; Da-Wei Ye
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

2.  Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.

Authors:  Kumiko Shirai; Hayato Hikita; Sadatsugu Sakane; Ryohei Narumi; Jun Adachi; Akira Doi; Satoshi Tanaka; Yuki Tahata; Ryoko Yamada; Takahiro Kodama; Ryotaro Sakamori; Tomohide Tatsumi; Eiji Mita; Takeshi Tomonaga; Tetsuo Takehara
Journal:  PLoS One       Date:  2022-07-07       Impact factor: 3.752

Review 3.  Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis.

Authors:  Emma Reungoat; Boyan Grigorov; Fabien Zoulim; Eve-Isabelle Pécheur
Journal:  Cancers (Basel)       Date:  2021-05-09       Impact factor: 6.639

Review 4.  Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma.

Authors:  Alberto Zanetto; Elena Campello; Luca Spiezia; Patrizia Burra; Paolo Simioni; Francesco Paolo Russo
Journal:  Cancers (Basel)       Date:  2018-11-16       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.